https://www.mayoclinic.org/tests-procedures/breast-biopsy/about/pac-20384812

Breast biopsy needle sampling is standing at the crossroads of a technological revolution. The traditional image-guided + manual puncture mode is rapidly evolving towards intelligence, precision, minimally invasive, and functional directions. The future biopsy needle will no longer be a simple cutting tool, but an intelligent platform that integrates diagnosis, analysis, and treatment.

I. Artificial Intelligence Empowerment: From "Human Eye Recognition" to "Algorithm Navigation"

Artificial intelligence is profoundly transforming the way image guidance is conducted. Future biopsy systems will incorporate deep learning algorithms, enabling them to automatically identify, segment, and mark suspicious lesions on ultrasound, mammography, or MRI images, and even predict their malignancy probability. During the puncture process, the AI system can track the needle tip position in real time and compare it with the pre-planned path. If there is any deviation, it will issue an alert. This is equivalent to equipping doctors with an "assistant driver" that is never tired and has extremely powerful computing capabilities, significantly reducing human errors, especially for beginners and inexperienced doctors.

II. Vacuum-assisted and Rotary Cutting Technology: From "Single-point Sampling" to "Whole Piece Removal"

The current mainstream vacuum-assisted biopsy systems can now suck the tissue into the collection chamber through negative pressure for rotary cutting, obtaining larger and more complete samples than those obtained by ordinary core needles. The future development direction is to achieve "minimally invasive resection guided by imaging." That is, for some small and benign lesions (such as fibroadenomas smaller than 2 centimeters), they can be directly completely removed through a large-diameter vacuum-assisted rotary biopsy needle, achieving both diagnostic and therapeutic purposes, truly realizing "one needle for both diagnosis and treatment," and eliminating the pain of traditional open surgeries.

III. Molecular and Optical Biopsies: From "Morphology" to "Function"

Traditional biopsies can only provide information on the tissue morphology. The new generation of "smart biopsy needles" are attempting to integrate micro-sensors to achieve "instant optical biopsy." For instance, a micro-spectrometer can be integrated at the needle tip. By analyzing the absorption and scattering characteristics of the tissue to specific wavelengths of light, it can determine whether the tissue is normal, hyperplastic, or cancerous within a few seconds. Another approach is to utilize Raman spectroscopy technology to detect the unique molecular fingerprints of cancer cells. These technologies are expected to provide real-time diagnostic information simultaneously during the puncture, significantly reducing the waiting time for pathological results, and even achieving "seeing is believing."

IV. Integration of Liquid Biopsy and Tissue Biopsy: From "Invasive" to "Minimally Invasive Combined"

Although tissue biopsy is the gold standard, it is still an invasive procedure. The future trend is to combine tissue biopsy with liquid biopsy (which detects circulating tumor cells or DNA in the blood). While performing a breast biopsy needle sampling, a small amount of blood sample from the surrounding area of the tumor can be collected through the side hole of the same needle for liquid biopsy analysis. This "double biopsy" model can provide more comprehensive tumor information: tissue biopsy examines "static" cell morphology and gene mutations, while liquid biopsy examines "dynamic" tumor load and drug resistance evolution, providing a basis for dynamic monitoring of treatment effects.

V. Targeted Drug Delivery: From "Diagnostic Tools" to "Therapeutic Platforms"

The most revolutionary idea is to transform the biopsy needle into a precise drug delivery vehicle. Once it is confirmed that the lesion is malignant, chemotherapy drugs, targeted drugs, or immunomodulators can be directly injected into the core of the tumor through the central channel of the biopsy needle. This "intratumoral drug delivery" method can significantly increase the local drug concentration while reducing systemic toxicity. Combined with nanotechnology and temperature-controlled sustained-release technology, it is even possible to achieve on-demand drug release, allowing a single biopsy needle to complete all the tasks of diagnosis, staging, genetic analysis, and local treatment simultaneously.

Summary

The future of breast biopsy needle sampling technology is a multifunctional intelligent platform integrating artificial intelligence, optical sensing, minimally invasive engineering, and drug delivery. It will no longer merely be a means of obtaining tissue samples, but will instead become a bridge connecting diagnosis and treatment, leading the diagnosis and treatment of breast diseases into an unprecedented era of precision, efficiency, and humanization.